BTIG Maintains Buy on AVITA Medical, Raises Price Target to $21
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice Target
BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $15 to $21.
BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $15 to $21.